2026 H1 - tulosraportti
19 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 1 168 | - | - | ||
| 1 386 | - | - | ||
| 378 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sitten · MuokattuLast time TM had a directed issue followed by a repair issue, quite strong news came afterwards which led to a near doubling of the issue price. This proves that TM takes care of its shareholders, and my thought is that if this repair issue is cancelled, they will show exactly why one should have participated when these unavoidable news regarding expansion in the USA come. This will create a large vacuum as all shares for sale will be sucked up when the market prices in the enormous market Thor is about to enter. It's not just one thing they sell! They sell an entire chain, which gives them the first foothold as a private player in the USA in exactly this field. In the USA, it is so incredibly much more privatized than in Norway. One can imagine how many will want Thor's products, as the American state itself is the only major supplier (as far as I understand it), and if I know the Trump administration correctly, their price is not particularly cheap as they almost have to ration the products to customers (haven't checked this exact fact about price, so please correct me). I completely agree that if this repair issue is still carried out, many larger players who did not get to participate in the directed issue will subscribe, precisely because they want larger quantities, and there are generally few shares to pick up in the 4.6-4.8 area except during times when short selling rages. Also remember that Thor's technology makes it cheaper and cleaner. I believe medical companies that WILL manage it will buy from them, because they don't want unnecessary sources of error. These are just my thoughts, not investment advice.
·5 t sittenPerspective and Merck will run Pb-212 together with Keytruda. The candidate is named PSV359. It targets FAP-α in lung and colorectal cancer. The study is ongoing, phase 1/2a. Merck provides Keytruda. Perspective owns the protocol. Merck is MSD. One of the largest in the world, Keytruda is the cancer drug everyone knows. They are not buying the company. They are testing if alpha can open tumors Keytruda doesn't target alone. Perspective sources the isotope from DOE, not from Thor. Nevertheless: when Merck is involved, Pb-212 is in with big pharma. This means more patients and more need for Th-228 over time. https://www.globenewswire.com/news-release/2026/09/14/3360885/0/en/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pb-psv359-in-combination-with-keytruda-pembrolizumab-in-fap-%ce%b1-positive-soli.html
5 t sittenI view Merck’s involvement in Perspective Therapeutics’ program as more than just routine research news. It is yet another signal that major oncology companies are beginning to regard Pb-212-based alpha therapies—and combinations thereof—as a serious treatment modality.
·10 t sittenWhen filtering for new investors last week at Norne Securities, a quite interesting mix appears in TRMED. This comes after the 300 million emission and the return of shares, so the register is naturally shifting now. Nevertheless, there are several names here worth noting. This is what the positions look like in the overview: Olili AS: approx. 7.93 million shares (1.88 %), value around 37.6 million. This is Richard Felix Heinrich, the Backstube founder. He is not new to the stock, but one of those who has held a significant position over time. Christian Johnsen: approx. 2.94 million shares (0.70 %), value around 14 million. Songa Capital AS: approx. 1.75 million shares (0.41 %), value around 8.3 million. This is the Blystad group's investment company. A truly quality name. J.P. Morgan Securities: approx. 1.55 million shares (0.37 %). J.P. Morgan SE: approx. 1.52 million shares (0.36 %). These are nominee accounts, so the real owners are behind them. Lars Petter Haugen: approx. 1.30 million shares (0.31 %), value around 6.2 million. Bank of New York: approx. 1.08 million shares (0.26 %), also nominee. Arctic Securities: 1.00 million shares (0.24 %). They were the facilitator in the emission, so this might be related to settlement and client accounts. Olav Olsen Holding: 1.00 million shares (0.24 %). Olav Aksel Olsen, an active small-cap investor who has also been involved in other growth companies. What is positive is that both well-known Norwegian money and more institutional structure are coming in after AlphaOne is up and running and the company has raised capital for its US venture. To me, it looks like the ownership side is starting to professionalize. That's exactly what you want to see at the beginning of an industrial adventure. 🫡✨️
And what we know about both Olili and Johnsen is that they are out again as soon as the share has gone up a couple of kroner. Whether they have 5-10 or 15 million shares. The former is skilled and is probably the one who has earned by far the most on entry and exit in Thor.
·11 t sittenNow there will probably soon be an announcement that the rights issue will be cancelled....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
19 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten · MuokattuLast time TM had a directed issue followed by a repair issue, quite strong news came afterwards which led to a near doubling of the issue price. This proves that TM takes care of its shareholders, and my thought is that if this repair issue is cancelled, they will show exactly why one should have participated when these unavoidable news regarding expansion in the USA come. This will create a large vacuum as all shares for sale will be sucked up when the market prices in the enormous market Thor is about to enter. It's not just one thing they sell! They sell an entire chain, which gives them the first foothold as a private player in the USA in exactly this field. In the USA, it is so incredibly much more privatized than in Norway. One can imagine how many will want Thor's products, as the American state itself is the only major supplier (as far as I understand it), and if I know the Trump administration correctly, their price is not particularly cheap as they almost have to ration the products to customers (haven't checked this exact fact about price, so please correct me). I completely agree that if this repair issue is still carried out, many larger players who did not get to participate in the directed issue will subscribe, precisely because they want larger quantities, and there are generally few shares to pick up in the 4.6-4.8 area except during times when short selling rages. Also remember that Thor's technology makes it cheaper and cleaner. I believe medical companies that WILL manage it will buy from them, because they don't want unnecessary sources of error. These are just my thoughts, not investment advice.
- ·5 t sittenPerspective and Merck will run Pb-212 together with Keytruda. The candidate is named PSV359. It targets FAP-α in lung and colorectal cancer. The study is ongoing, phase 1/2a. Merck provides Keytruda. Perspective owns the protocol. Merck is MSD. One of the largest in the world, Keytruda is the cancer drug everyone knows. They are not buying the company. They are testing if alpha can open tumors Keytruda doesn't target alone. Perspective sources the isotope from DOE, not from Thor. Nevertheless: when Merck is involved, Pb-212 is in with big pharma. This means more patients and more need for Th-228 over time. https://www.globenewswire.com/news-release/2026/09/14/3360885/0/en/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pb-psv359-in-combination-with-keytruda-pembrolizumab-in-fap-%ce%b1-positive-soli.html5 t sittenI view Merck’s involvement in Perspective Therapeutics’ program as more than just routine research news. It is yet another signal that major oncology companies are beginning to regard Pb-212-based alpha therapies—and combinations thereof—as a serious treatment modality.
- ·10 t sittenWhen filtering for new investors last week at Norne Securities, a quite interesting mix appears in TRMED. This comes after the 300 million emission and the return of shares, so the register is naturally shifting now. Nevertheless, there are several names here worth noting. This is what the positions look like in the overview: Olili AS: approx. 7.93 million shares (1.88 %), value around 37.6 million. This is Richard Felix Heinrich, the Backstube founder. He is not new to the stock, but one of those who has held a significant position over time. Christian Johnsen: approx. 2.94 million shares (0.70 %), value around 14 million. Songa Capital AS: approx. 1.75 million shares (0.41 %), value around 8.3 million. This is the Blystad group's investment company. A truly quality name. J.P. Morgan Securities: approx. 1.55 million shares (0.37 %). J.P. Morgan SE: approx. 1.52 million shares (0.36 %). These are nominee accounts, so the real owners are behind them. Lars Petter Haugen: approx. 1.30 million shares (0.31 %), value around 6.2 million. Bank of New York: approx. 1.08 million shares (0.26 %), also nominee. Arctic Securities: 1.00 million shares (0.24 %). They were the facilitator in the emission, so this might be related to settlement and client accounts. Olav Olsen Holding: 1.00 million shares (0.24 %). Olav Aksel Olsen, an active small-cap investor who has also been involved in other growth companies. What is positive is that both well-known Norwegian money and more institutional structure are coming in after AlphaOne is up and running and the company has raised capital for its US venture. To me, it looks like the ownership side is starting to professionalize. That's exactly what you want to see at the beginning of an industrial adventure. 🫡✨️And what we know about both Olili and Johnsen is that they are out again as soon as the share has gone up a couple of kroner. Whether they have 5-10 or 15 million shares. The former is skilled and is probably the one who has earned by far the most on entry and exit in Thor.
- ·11 t sittenNow there will probably soon be an announcement that the rights issue will be cancelled....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 1 168 | - | - | ||
| 1 386 | - | - | ||
| 378 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
19 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten · MuokattuLast time TM had a directed issue followed by a repair issue, quite strong news came afterwards which led to a near doubling of the issue price. This proves that TM takes care of its shareholders, and my thought is that if this repair issue is cancelled, they will show exactly why one should have participated when these unavoidable news regarding expansion in the USA come. This will create a large vacuum as all shares for sale will be sucked up when the market prices in the enormous market Thor is about to enter. It's not just one thing they sell! They sell an entire chain, which gives them the first foothold as a private player in the USA in exactly this field. In the USA, it is so incredibly much more privatized than in Norway. One can imagine how many will want Thor's products, as the American state itself is the only major supplier (as far as I understand it), and if I know the Trump administration correctly, their price is not particularly cheap as they almost have to ration the products to customers (haven't checked this exact fact about price, so please correct me). I completely agree that if this repair issue is still carried out, many larger players who did not get to participate in the directed issue will subscribe, precisely because they want larger quantities, and there are generally few shares to pick up in the 4.6-4.8 area except during times when short selling rages. Also remember that Thor's technology makes it cheaper and cleaner. I believe medical companies that WILL manage it will buy from them, because they don't want unnecessary sources of error. These are just my thoughts, not investment advice.
- ·5 t sittenPerspective and Merck will run Pb-212 together with Keytruda. The candidate is named PSV359. It targets FAP-α in lung and colorectal cancer. The study is ongoing, phase 1/2a. Merck provides Keytruda. Perspective owns the protocol. Merck is MSD. One of the largest in the world, Keytruda is the cancer drug everyone knows. They are not buying the company. They are testing if alpha can open tumors Keytruda doesn't target alone. Perspective sources the isotope from DOE, not from Thor. Nevertheless: when Merck is involved, Pb-212 is in with big pharma. This means more patients and more need for Th-228 over time. https://www.globenewswire.com/news-release/2026/09/14/3360885/0/en/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pb-psv359-in-combination-with-keytruda-pembrolizumab-in-fap-%ce%b1-positive-soli.html5 t sittenI view Merck’s involvement in Perspective Therapeutics’ program as more than just routine research news. It is yet another signal that major oncology companies are beginning to regard Pb-212-based alpha therapies—and combinations thereof—as a serious treatment modality.
- ·10 t sittenWhen filtering for new investors last week at Norne Securities, a quite interesting mix appears in TRMED. This comes after the 300 million emission and the return of shares, so the register is naturally shifting now. Nevertheless, there are several names here worth noting. This is what the positions look like in the overview: Olili AS: approx. 7.93 million shares (1.88 %), value around 37.6 million. This is Richard Felix Heinrich, the Backstube founder. He is not new to the stock, but one of those who has held a significant position over time. Christian Johnsen: approx. 2.94 million shares (0.70 %), value around 14 million. Songa Capital AS: approx. 1.75 million shares (0.41 %), value around 8.3 million. This is the Blystad group's investment company. A truly quality name. J.P. Morgan Securities: approx. 1.55 million shares (0.37 %). J.P. Morgan SE: approx. 1.52 million shares (0.36 %). These are nominee accounts, so the real owners are behind them. Lars Petter Haugen: approx. 1.30 million shares (0.31 %), value around 6.2 million. Bank of New York: approx. 1.08 million shares (0.26 %), also nominee. Arctic Securities: 1.00 million shares (0.24 %). They were the facilitator in the emission, so this might be related to settlement and client accounts. Olav Olsen Holding: 1.00 million shares (0.24 %). Olav Aksel Olsen, an active small-cap investor who has also been involved in other growth companies. What is positive is that both well-known Norwegian money and more institutional structure are coming in after AlphaOne is up and running and the company has raised capital for its US venture. To me, it looks like the ownership side is starting to professionalize. That's exactly what you want to see at the beginning of an industrial adventure. 🫡✨️And what we know about both Olili and Johnsen is that they are out again as soon as the share has gone up a couple of kroner. Whether they have 5-10 or 15 million shares. The former is skilled and is probably the one who has earned by far the most on entry and exit in Thor.
- ·11 t sittenNow there will probably soon be an announcement that the rights issue will be cancelled....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 1 168 | - | - | ||
| 1 386 | - | - | ||
| 378 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt